U.S., Aug. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07788404) titled 'Population Pharmacokinetic Model of Rifampicin in Staphylococcal Osteoarticular Infections' on May 06.
Brief Summary: Staphylococcal osteoarticular infections (OAIs), including prosthetic joint infections and chronic osteomyelitis, represent a major cause of morbidity. Rifampicin is a key bactericidal antibiotic effective against staphylococcal biofilm. However, its pharmacokinetics exhibit substantial inter-individual variability due to complex hepatic metabolism and drug interactions. Currently, no prospective population pharmacokinetic (PopPK) model of rifampicin combined with levofloxacin or ciprofloxacin exists in patients with...